Fat Loss

Also known as: Triple Agonist, GLP-3, 4x Blend, RC-3R, PEP-3R, GLP-3 RT, GLP-R, Ion Peptide Retatrutide, GIP/GLP/Glucagon, ION-3R, GLP-3R, Retatrutide, Reta

Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly. Where Semaglutide activates GLP-1 alone and Tirzepatide activates both GLP-1 and GIP, retatrutide adds glucagon receptor agonism for synergistic effects on energy expenditure, hepatic lipid metabolism, and weight reduction. As of April 2026, retatrutide is not FDA-approved — it remains in Phase 3 clinical development. Eli Lilly's TRIUMPH program is evaluating retatrutide for obesity, type 2 diabetes, NAFLD/MASH, and chronic kidney disease. The lead obesity indication (TRIUMPH-1) is expected to complete in 2026-2027 with potential FDA submission shortly thereafter. The clinical excitement around retatrutide is driven by the Phase 2 obesity trial data published in NEJM in 2023: participants on retatrutide 12 mg weekly achieved 24.2% body weight reduction at 48 weeks — the largest weight loss demonstrated by any non-surgical intervention to date, exceeding both semaglutide (~15% at 68 weeks in STEP-1) and tirzepatide (~21% at 72 weeks in SURMOUNT-1) (Jastreboff et al., 2023). Despite the strong efficacy signal, retatrutide's triple-receptor profile carries distinct safety considerations beyond the GLP-1 class: Heart rate elevation — mean ~6-8 bpm increase (larger than semaglutide or tirzepatide), likely driven by the glucagon-receptor component Transient elevation of fasting glucose during uptitration (glucagon receptor effect on hepatic glucose output) — usually self-limited Higher rate of GI adverse events at the 12 mg maximal dose compared to lower doses and compared to GLP-1-only agents Unknown long-term cardiovascular outcomes — large Phase 3 cardiovascular outcome trials are ongoing Regulatory status: Not FDA-approved. Available only through clinical trials, research-chemical channels, and (controversially) compounding pharmacies in some jurisdictions using non-commercial retatrutide sourcing. The FDA has not announced an approval pathway timeline. Typical dosing (extrapolated from Phase 2 uptitration schedule): starting 2 mg weekly SC, titrating to 8-12 mg weekly over 12-20 weeks. The maximal dose of 12 mg weekly is associated with the largest weight loss and the largest side-effect burden. See our Retatrutide Dosage Guide for uptitration specifics and our Semaglutide vs Tirzepatide vs Retatrutide comparison for class-selection context.

Also known as: NS2330

Tesofensine (NS2330) is an orally-administered small-molecule triple monoamine reuptake inhibitor — it blocks the reuptake of noradrenaline, dopamine, and serotonin, placing it in the same broad pharmacologic class as sibutramine (withdrawn 2010 for cardiovascular risk) but with a different receptor-affinity profile and markedly longer half-life. Originally developed by Danish company NeuroSearch in the late 1990s as a treatment for Alzheimer's disease and Parkinson's disease, tesofensine failed both neurology indications in Phase 2 trials. What rescued the compound from shelf-abandonment was an incidental observation across those failed neurology programs: patients consistently lost weight on tesofensine, often substantially, despite losing weight not being a primary or secondary endpoint. That signal triggered repositioning toward obesity, culminating in a 2008 Phase 2B trial (TIPO-1) published in The Lancet that remains one of the most-cited papers in modern obesity pharmacology (Astrup et al., 2008). The trial enrolled 203 obese adults randomized to tesofensine 0.25 mg, 0.5 mg, 1.0 mg daily or placebo plus a hypocaloric diet, and reported mean 24-week weight loss of 6.7%, 11.3%, and 12.8% at the three active doses vs 2.2% for placebo — roughly double what any other obesity drug was producing at the time and within striking distance of early bariatric surgery results. The magnitude of the effect generated substantial commercial interest and positioned tesofensine as potentially the first "surgery-competitive" weight-loss drug. However, the 1 mg dose produced clinically meaningful increases in heart rate and blood pressure, raising the cardiovascular safety concerns that had already led to sibutramine's withdrawal. FDA and EMA did not approve tesofensine, and the Phase 3 program stalled. NeuroSearch divested the compound to Saniona (Danish biotech), which continued development and achieved regulatory approval in Mexico (marketed as Tesomet for Prader-Willi syndrome-associated obesity) but not in the US or Europe as of 2026. Tesofensine has since become a widely-traded research chemical, with unapproved-market use for weight loss despite the unresolved cardiovascular signal and limited Phase 3 safety data. Cross-references include Semaglutide and Tirzepatide (approved GLP-1-class alternatives with stronger safety profiles), Retatrutide (investigational triple agonist), Orforglipron (oral GLP-1 agonist), Cagrilintide (amylin analog), and AOD-9604 (another repurposed failure). For stimulant-class cognitive context see Modafinil and Methylphenidate.

Also known as: GLP-1S, GLP-1 Agonist, RC-1S, PEP-1S, ION-1S, Ion Peptide Semaglutide, GLP-1, Semaglutide, Sema

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185). Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide (PMID: 35658024). Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.

Also known as: GLP-2T, GIP/GLP-1, ION-2T, GLP-2, Tirzepatide, PEP-2T, RC-2T, Dual Agonist, Ion Peptide Tirzepatide, Tirz, GIP/GLP

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer activity at both GIP and GLP-1 receptors. Tirzepatide features a C20 fatty diacid moiety attached via a linker to facilitate albumin binding, resulting in a plasma half-life of approximately 5 days that supports once-weekly subcutaneous dosing. Tirzepatide is FDA-approved under two brand names: Mounjaro (for type 2 diabetes mellitus, approved May 2022) and Zepbound (for chronic weight management, approved November 2023). It is manufactured by Eli Lilly and Company and represents the first-in-class dual GIP/GLP-1 receptor agonist to reach the market. The SURMOUNT clinical trial program established tirzepatide as the most effective pharmacological weight loss agent to date. In the SURMOUNT-1 trial, participants with obesity or overweight (without diabetes) receiving tirzepatide 15 mg weekly achieved a mean body weight reduction of 22.5% from baseline at 72 weeks, compared to 2.4% with placebo — a treatment difference of 20.1 percentage points. Notably, 36.2% of participants in the 15 mg group achieved 25% or greater total body weight loss, approaching the magnitude historically seen only with bariatric surgery (PMID: 35658024). The SURMOUNT-2 trial evaluated tirzepatide in adults with type 2 diabetes and obesity, demonstrating mean weight loss of 14.7% with tirzepatide 15 mg versus 3.2% with placebo at 72 weeks, along with significant HbA1c improvement (PMID: 36519860). The SURMOUNT-3 trial studied tirzepatide following an intensive 12-week lifestyle intervention, showing that tirzepatide maintained and extended initial weight loss while placebo recipients regained weight (PMID: 37840095). A key differentiating feature of tirzepatide compared to pure GLP-1 receptor agonists such as semaglutide is the GIP receptor agonist component. GIP signaling in adipose tissue is proposed to improve lipid metabolism and may protect against the loss of lean body mass that accompanies caloric restriction and weight loss. Preclinical and early clinical data suggest that tirzepatide-treated patients lose a greater proportion of fat mass relative to lean mass compared to GLP-1-only agents, though this finding requires further validation in dedicated body composition studies. Tirzepatide achieved the highest absolute weight loss of any anti-obesity medication in clinical trials. At the 15 mg dose, mean absolute weight loss was approximately 24 kg (52 lbs) at 72 weeks in SURMOUNT-1. The gastrointestinal side effect profile is similar to GLP-1 receptor agonists, with nausea being the most common adverse event, generally mild to moderate and diminishing over time with dose titration.

Also known as: LY3305677

Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan. Structurally it is a 39-amino-acid synthetic peptide based on the oxyntomodulin scaffold — the natural L-cell gut hormone that shares its first 29 residues with glucagon and has intrinsic dual GLP-1/glucagon activity — with strategic modifications including lipid conjugation (similar to semaglutide and liraglutide) for extended half-life, enabling once-weekly subcutaneous administration. Mazdutide represents a different mechanistic philosophy from tirzepatide and semaglutide: while those drugs use GLP-1 signaling (sometimes with GIP in tirzepatide's case), mazdutide adds glucagon receptor agonism, which increases resting energy expenditure and promotes hepatic lipid utilization — in essence, combining appetite suppression (GLP-1) with increased metabolic rate and fat burning (glucagon). The rationale for dual GLP-1/glucagon agonism goes back to the 1970s observation that oxyntomodulin administered to humans reduced food intake and body weight more than GLP-1 alone. Pure glucagon agonism has historically been avoided in diabetes drug development because glucagon raises blood glucose; however, GLP-1 signaling simultaneously stimulates insulin secretion and suppresses glucagon release, creating a counterbalancing effect when the two are combined in a single molecule. The net result in humans is that dual GLP-1/glucagon agonists like mazdutide produce weight loss comparable to semaglutide while also improving hepatic steatosis, raising energy expenditure ~5-8% above baseline, and delivering glycemic control at least as good as GLP-1 monotherapy. A related and more advanced triple agonist, Retatrutide, adds GIP activity and has shown even more dramatic weight loss in Phase 2 (~24% at 48 weeks) but is developed by Eli Lilly directly rather than licensed regionally. Mazdutide's Phase 3 development in China has been rapid. The DREAMS-1 (obesity) and DREAMS-2 (type 2 diabetes + obesity) trials enrolled Chinese patients and delivered strong results. In DREAMS-1, 9 mg weekly mazdutide produced mean weight loss of ~15% at 48 weeks in adults with obesity (BMI ≥28 kg/m² per Chinese classification) — closely comparable to semaglutide's Western trial results. In GLORY-1, a Phase 3 trial of 6 mg mazdutide in overweight/obese adults, weight reduction was 14.4% at 48 weeks versus 0.3% placebo (Ji et al., 2024). NMPA (China's FDA equivalent) approval in China is expected in 2025-2026, positioning mazdutide as the first major incretin-class drug developed specifically for the Chinese population and potentially the first dual GLP-1/glucagon agonist to reach market globally (ahead of Eli Lilly's retatrutide triple agonist). Whether mazdutide will be developed or licensed for Western markets remains an open commercial question — Lilly retained rights outside the Innovent territories but has prioritized retatrutide. Cross-references include Semaglutide (GLP-1 monoagonist competitor), Tirzepatide (GLP-1/GIP dual agonist competitor), Retatrutide (Lilly's GLP-1/GIP/glucagon triple agonist), Cagrilintide (amylin analog in CagriSema combination), and Orforglipron (oral non-peptide GLP-1 agonist).

Orforglipron (also known as LY3502970) is Eli Lilly's investigational oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity and type 2 diabetes. Unlike virtually every other GLP-1 receptor agonist on the market — Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, exenatide — which are peptide-based and require either subcutaneous injection or strict oral dosing conditions to survive gastric degradation, orforglipron is a small molecule with a molecular weight of approximately 563 Daltons. It binds the GLP-1 receptor at an allosteric site distinct from the orthosteric site used by the native peptide, producing full agonist activity without needing the peptide's complex 3D structure. This pharmacology delivers two transformational advantages: (1) it can be taken as a once-daily pill without food or beverage restrictions, and (2) it does not require refrigeration, cold-chain distribution, or manufacturing capacity constrained to specialized peptide synthesis — solving two of the biggest barriers to global GLP-1 access. Orforglipron's Phase 3 ACHIEVE and ATTAIN programs completed primary readouts in 2025, with results that effectively validate oral non-peptide GLP-1 receptor agonism as clinically equivalent to injectable peptide analogs. In ATTAIN-1 (obesity), 36 mg orforglipron once daily produced mean weight loss of 14.7% at 72 weeks in adults with obesity but without diabetes — remarkably close to the 15-17% typical of subcutaneous semaglutide 2.4 mg weekly (Wegovy) and within striking distance of tirzepatide's 15-20% range at comparable doses. In ACHIEVE-1 (type 2 diabetes), orforglipron at 12 mg, 24 mg, and 36 mg doses delivered HbA1c reductions of ~1.3%, ~1.6%, and ~1.8% respectively over 40 weeks, alongside 4-8% weight loss. These results position orforglipron as the first oral non-peptide GLP-1 to demonstrate injectable-class efficacy, setting up probable FDA and EMA filings in 2025-2026 with potential first approvals in 2026. Why this matters commercially and clinically: the current GLP-1 supply crisis — semaglutide shortages lasted 2+ years, tirzepatide manufacturing is still constrained — stems from peptide synthesis capacity. Small-molecule orforglipron can be manufactured in traditional API facilities using standard organic chemistry, dramatically expanding global supply, reducing cost-of-goods, and enabling distribution to low- and middle-income countries where refrigerated peptides are logistically difficult. A generic-analog small-molecule GLP-1 class could ultimately bring retail cost from $1,000+/month for brand-name injectables to potentially under $50/month for oral generics — with parallels to how statins democratized cholesterol management. Cross-references include Semaglutide (injectable GLP-1 peptide), Tirzepatide (injectable GLP-1/GIP peptide), Mazdutide (injectable GLP-1/glucagon peptide for China), Retatrutide (injectable GLP-1/GIP/glucagon triple agonist peptide), and Cagrilintide (amylin analog used in combination with GLP-1s).

Also known as: NN9838

Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema. It represents the first clinically successful revival of amylin pharmacology since pramlintide (Symlin) was approved in 2005 for type 1 and type 2 diabetes — a product that never achieved commercial success largely because of its inconvenient three-times-daily subcutaneous dosing schedule and its narrow label. Cagrilintide solves the pharmacokinetic problem: through acylation with a fatty acid chain (in a strategy similar to Novo Nordisk's use of the same chemistry in semaglutide and insulin degludec), cagrilintide binds reversibly to albumin, extending its half-life from native amylin's 13 minutes to approximately 159 hours (6-7 days), enabling once-weekly subcutaneous injection (Enebo et al., 2021). Amylin itself is a 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient ingestion, at roughly 1-5% the molar ratio of insulin. It was discovered in 1987 by Per Westermark and colleagues as the principal constituent of pancreatic amyloid deposits in type 2 diabetes (hence the name amylin — from amyloid). The mature hormone contains a disulfide bond between cysteine-2 and cysteine-7 and a C-terminal amide essential for bioactivity, giving it a cyclic head and a linear tail. Native amylin is aggregation-prone and forms the same toxic oligomers and fibrils implicated in beta-cell failure, which is why all clinical amylin analogs (pramlintide, cagrilintide, amycretin) have substituted key amyloidogenic residues (typically proline substitutions at positions 25, 28, 29) to block the fibrillation pathway while preserving receptor binding. In the Phase 2 randomized trial of cagrilintide monotherapy at 4.5 mg weekly in adults with obesity, mean weight loss at 26 weeks was approximately 10.8% versus 3.0% with placebo and 9.0% with liraglutide 3.0 mg daily (Lau et al., 2021). More importantly, the CagriSema Phase 2 combination trial — cagrilintide 2.4 mg + semaglutide 2.4 mg weekly — produced 15.6% placebo-adjusted weight loss at 32 weeks, substantially greater than either component alone and comparable to tirzepatide and retatrutide results, generating intense pharma-industry and investor interest (Enebo et al., 2021). The Phase 3 REDEFINE program (REDEFINE 1, 2, 3, 4) has enrolled over 6,000 participants, with REDEFINE 1 (adults with obesity, no diabetes) and REDEFINE 2 (type 2 diabetes) reading out weight loss endpoints of 22.7% at 68 weeks in the landmark cohort, positioning CagriSema to compete with tirzepatide (Zepbound/Mounjaro) and the emerging triple agonist retatrutide as the next-generation incretin-amylin combination therapy. Cross-references include Semaglutide (the GLP-1 component of CagriSema), Tirzepatide (the leading dual GLP-1/GIP competitor), Retatrutide (triple agonist in development), Mazdutide (GLP-1/glucagon dual agonist from Innovent), and Orforglipron (oral non-peptide GLP-1 agonist).

Also known as: Satiora, GLP-1 Spray

GLP-1 receptor agonist used for metabolic effect and appetite regulation.

Also known as: AOD9604, Burn Balm

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). It was developed in the 1990s-2000s by Professor Frank Ng and colleagues at the Howard Florey Institute (University of Melbourne) and commercialized by Metabolic Pharmaceuticals Australia with the specific goal of isolating the "lipolytic" (fat-burning) domain of growth hormone while separating it from the "growth-promoting" domain that drives IGF-1-mediated effects, glucose intolerance, and soft-tissue growth. The underlying scientific rationale came from a series of studies in the 1980s-1990s showing that specific C-terminal fragments of hGH retained the fat-metabolism-improving effects of full-length hGH in rodent models without causing IGF-1 elevation, glucose intolerance, or cartilage/organ growth (Ng et al., 2000). Despite this attractive preclinical profile, AOD-9604's clinical trial history has been disappointing. The key Phase 2B trial published in 2008 enrolled 536 obese adults and tested AOD-9604 at doses of 1 mg and 30 mg subcutaneously daily for 24 weeks versus placebo; none of the doses produced statistically significant weight loss over placebo (Heffernan et al., 2008). The trial was a commercial and clinical failure, leading Metabolic Pharmaceuticals to abandon obesity development and ultimately exit the pharmaceutical business entirely. AOD-9604 was never approved as a drug in any country for any indication. However, AOD-9604 has enjoyed a peculiar second life in two contexts: (1) as a marketed ingredient in oral supplements claiming "fat burning" properties in the US following FDA's 2014 GRAS (Generally Recognized as Safe) determination for use as a food ingredient at low doses — a determination that did not assess efficacy, only safety; and (2) as a widely-marketed research peptide sold by "research chemical" suppliers for injectable use at peptide-tuning doses (250-500 mcg daily), typically combined in stacks with other compounds for body composition tuning. Notably, the GRAS designation for oral consumption is scientifically odd given that AOD-9604 is a peptide that would be expected to be degraded by gastric acid and digestive proteases with minimal systemic bioavailability — effectively meaning oral AOD-9604 supplements likely deliver negligible active peptide to the circulation. Cross-references include Tesamorelin (FDA-approved GHRH analog for visceral fat with genuine clinical evidence), Ipamorelin (GH secretagogue with pulsatile release), CJC-1295 (long-acting GHRH analog), Sermorelin (GHRH analog), MOTS-c (mitochondrial metabolic peptide), and 5-Amino-1MQ (NNMT inhibitor for fat loss).

HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity. The sequence spans residues 176 through 191 of native hGH plus the tyrosine cap, giving the designation "Tyr-hGH 176-191." It was developed in the 1990s at Monash University (Melbourne, Australia) under the direction of F.M. Ng and colleagues, and subsequently licensed to Metabolic Pharmaceuticals (later acquired by Calzada Ltd), which pursued clinical development for obesity indications. The core hypothesis driving its development was that the C-terminal region of hGH carries the lipolytic (fat-burning) and anti-lipogenic activity of the parent molecule while being separable from the IGF-1-mediated growth-promoting effects that raise cancer, diabetes, and acromegaly concerns when full-length recombinant hGH is used chronically. That separation is real in cell culture and rodent studies. Ng and colleagues demonstrated in the 1990s that HGH 176-191 stimulates lipolysis in isolated adipocytes, reduces body fat in genetically obese mice, and does so without measurably raising serum IGF-1 or activating the JAK2/STAT5 pathway in the growth-promoting way that intact hGH does. This work formed the scientific foundation for AOD-9604's clinical development as a potential obesity drug. Between approximately 2002 and 2008, Metabolic Pharmaceuticals conducted a series of Phase I and Phase II trials in humans, evaluating doses ranging from 100 mcg to 1 mg daily via subcutaneous injection and, in later studies, oral formulations. The critical fact users should understand is that AOD-9604 failed its key clinical trials. The 2007 Phase 2b trial (n≈534) evaluated AOD-9604 at doses up to 1 mg/day orally in obese adults over 24 weeks, and the primary endpoint — placebo-adjusted weight loss — was not met. The difference from placebo was small and not statistically significant. Metabolic Pharmaceuticals subsequently abandoned AOD-9604's development as an anti-obesity drug, and no regulatory agency (FDA, EMA, TGA, PMDA, Health Canada) has ever approved AOD-9604 for any indication. It is not an approved medicine anywhere in the world. The Australian TGA briefly granted AOD-9604 GRAS-like "listable" status as a cosmetic ingredient — a classification that does not imply clinical efficacy or safety for systemic therapeutic use — but this is a regulatory footnote, not a clinical endorsement. Notwithstanding the clinical trial failure, HGH Fragment 176-191 has acquired a significant following in the compounding pharmacy, peptide clinic, and research-chemical markets, primarily for claimed fat loss, joint health, and body recomposition effects. Compounding pharmacies in the United States have at times supplied AOD-9604 as an ingredient in custom formulations prescribed by longevity-medicine and functional-medicine physicians, though the FDA has issued guidance restricting compounding of peptides without an established USP or NF monograph, and the regulatory landscape for AOD-9604 compounding has tightened substantially since 2023. In the unregulated research-peptide market, HGH Fragment 176-191 is widely sold as an injectable peptide, typically at prices substantially lower than brand-name weight-loss medications. The problem users must grapple with is that the best-controlled human data on AOD-9604 showed it did not produce clinically meaningful weight loss. This is in stark contrast to the current standard of care for obesity, which includes the GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic) and the dual GIP/GLP-1 agonist tirzepatide (Zepbound, Mounjaro) — which produce 15-22% placebo-adjusted weight loss in 68-72 week randomised trials (STEP and SURMOUNT programmes), approved by the FDA, EMA, and global regulators for chronic weight management. These drugs have transformed obesity medicine in the 2020s. AOD-9604, by comparison, produced a weight-loss effect of approximately 2.8 kg vs. placebo in 12-week trials that did not reach the threshold for regulatory approval. The gap is not subtle; it is a categorical difference between an evidence-based treatment and a compound that failed its key trials. A more honest framing of AOD-9604 in 2026 is this: it is a rationally designed peptide fragment with plausible preclinical biology that did not translate to a clinically meaningful anti-obesity effect in humans. It may have subtle metabolic effects at commonly used research doses, but these have not been established in adequately powered, placebo-controlled trials. Users considering AOD-9604 for fat loss should first ask whether they have exhausted evidence-based options: GLP-1/GIP agonists for those meeting BMI criteria; structured diet and exercise programs with documented adherence support; evaluation of thyroid, cortisol, and metabolic status; and, where indicated, bariatric surgery consultation. Adding an unregulated peptide that failed its clinical trials is a substantially weaker option than any of these. For joint-health claims — a secondary use popularised in peptide-clinic marketing — there are no adequately powered trials establishing AOD-9604 efficacy for osteoarthritis or cartilage repair, and the evidence-based options (physical therapy, weight reduction, NSAIDs, intra-articular corticosteroids, and for eligible patients, joint replacement) remain the appropriate first-line. BPC-157 and TB-500 are sometimes discussed alongside AOD-9604 for joint and tissue-repair claims, but they share similar limitations in the evidence base. For the remainder of this page, we present the mechanism, studies, and protocols that users and compounding pharmacists have worked with — with the repeated caveat that none of this substitutes for a failed key trial result and the absence of any regulatory approval.

Also known as: Tesa, TH9507

Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH) — specifically the full 44-amino-acid GHRH sequence with a single N-terminal trans-3-hexenoyl fatty-acid modification. That modification protects the peptide from rapid dipeptidyl peptidase-4 (DPP-4) degradation, extending its circulating half-life to approximately 30 minutes (vs <2 minutes for native GHRH). Tesamorelin was developed by Theratechnologies and is marketed in the US as Egrifta (branded injectable) and Egrifta SV (updated formulation launched 2019). It is the only FDA-approved GHRH secretagogue in the United States, approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval was based on two Phase 3 trials showing ~18% reduction in visceral adipose tissue (VAT) at 26 weeks and sustained effect through 52 weeks (Falutz et al., 2007; Falutz et al., 2010). Unlike CJC-1295 with DAC, tesamorelin produces a pulsatile rather than sustained GH elevation. It preserves the negative-feedback regulation of the somatotroph axis because its half-life is short enough to clear between pulses, and this is the primary clinical reason it was developable as a long-term therapy where CJC-1295-DAC's continuous GH elevation raised safety concerns. Beyond the FDA-approved HIV lipodystrophy indication, tesamorelin is being studied and used off-label for: Non-alcoholic fatty liver disease (NAFLD / NASH) — Phase 2 trial showed reductions in hepatic fat fraction and liver enzymes (Stanley et al., 2014) HIV-associated cognitive decline — pilot data on executive function and memory (Adrian et al., 2018) General visceral adiposity in non-HIV metabolically-unhealthy adults (off-label biohacker use) Adjunct to CJC-1295 / MOD-GRF 1-29 + Ipamorelin stacks — when GHRH-only amplification is desired without the pulsatility trade-off of CJC-1295 with DAC Typical dosing: 2 mg subcutaneous once daily pre-bed (matches the FDA-approved protocol). Dose escalation above 2 mg/day has been studied but does not produce proportional IGF-1 elevation and raises fluid-retention burden. Regulatory status: FDA-approved for HIV lipodystrophy; available by prescription in the US. Biohacker use is off-label and typically sourced through compounding pharmacies or (controversially) research-chemical vendors. See our Tesamorelin Dosage Guide for protocol specifics.

Also known as: SLU PP 332

SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. The compound is the chemical scaffold from which the second-generation, orally bioavailable successor SLU-PP-915 was developed, and the SLU-PP-332 story is essential context for understanding the ERR agonist field because SLU-PP-332's original rodent pharmacology is what generated the initial enthusiasm for this drug class and its limitations (specifically its poor oral bioavailability) are what motivated the second-generation development program. The original publication from the Burris group established that SLU-PP-332 administration to mice produces a transcriptional, functional, and physiological signature that overlaps substantially with the effects of endurance exercise — enhanced running endurance on treadmill testing, increased mitochondrial biogenesis in skeletal muscle, shifts in muscle fiber type toward slow-twitch oxidative phenotype, elevated fatty acid oxidation, favorable body composition changes in diet-induced obesity models, and cardiac functional improvements in pressure-overload heart failure models. These effects are mediated through coordinated activation of the three ERR isoforms (ERRα, ERRβ, ERRγ), nuclear receptor transcription factors that sit at the top of the regulatory cascade controlling oxidative metabolism, and through recruitment of PGC-1α and other transcriptional coactivators that together drive expression of the exercise-responsive gene program. SLU-PP-332 specifically attracted intense scientific and popular media attention in 2023-2024 because the rodent data was presented in accessible terms — "a drug that mimics the effects of exercise" — and the social and medical appeal of such a compound for patients who cannot exercise due to frailty, cardiac disease, orthopedic limitations, or other constraints is obvious. The public discussion outran the evidence in typical fashion: the rodent data is real and consistent, but human validation of the exercise-mimetic premise requires clinical trials that have not been conducted for SLU-PP-332 or any related compound. SLU-PP-332's major pharmacological limitation, documented in the published work, is poor oral bioavailability. Every published rodent study with SLU-PP-332 used intraperitoneal (IP) injection as the route of administration, not oral dosing. IP administration in mice is routine in preclinical research but is obviously not a viable route for human chronic therapy, and this limitation was the specific motivation for the Burris group to develop the second-generation compound SLU-PP-915 with improved oral PK. The practical reality in April 2026 is that SLU-PP-332 remains a first-generation research chemical that has been largely superseded by SLU-PP-915 for self-experimentation purposes where oral dosing is preferred, though SLU-PP-332 continues to be sold by research-chemical vendors and used by a subset of biohackers who prefer the first-generation compound either for cost reasons, availability reasons, or preference for the more extensively characterized parent molecule. No human clinical trials of SLU-PP-332 have been registered or published, no IND applications for it have been publicly disclosed, and no pharmaceutical-grade supply exists. This entry covers the detailed mechanism of ERR pan-agonism as established in the original SLU-PP-332 work, the specific preclinical pharmacology including cardiovascular, metabolic, and musculoskeletal endpoints, the context provided by the broader ERR biology literature, the theoretical and practical concerns with self-administration of an unvalidated nuclear receptor agonist, how SLU-PP-332 differs practically from SLU-PP-915 for self-experimenters, and how SLU-PP-332 fits into the stacking landscape alongside other metabolic and exercise-mimetic interventions like 5-Amino-1MQ, BAM15, Humanin, L-Carnitine, Semaglutide, Tirzepatide, Retatrutide, and Tesofensine. The core takeaway is that SLU-PP-332 established a mechanistically compelling drug class for exercise-mimetic pharmacology, demonstrated consistent preclinical efficacy, and is limited in its current self-experimentation role by PK properties that are specifically addressed by the second-generation successor compound.

Also known as: 5-amino, NNMT inhibitor

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH). The compound emerged from a medicinal chemistry program at Sanofi aimed at developing NNMT inhibitors for metabolic disease, and was first described in the peer-reviewed literature in 2018 as one of several quinolinium-based inhibitors with single-digit micromolar potency against human NNMT in biochemical assays (Kannt et al., 2018; Neelakantan et al., 2017). Subsequent work characterized 5-amino-1MQ specifically as a bisubstrate-competitive inhibitor that occupies both the nicotinamide-binding pocket and extends into a portion of the SAM-binding site, providing selectivity over other methyltransferases in the body (Neelakantan et al., 2019). The interest in NNMT inhibition arose from observations that NNMT is overexpressed in adipose tissue, liver, and certain cancers, and that this overexpression contributes to metabolic dysfunction by depleting cellular NAD+ precursor pools and by altering the methyl donor balance that regulates epigenetic marks and lipid metabolism. In 2014, Kraus and colleagues demonstrated that adipocyte-specific NNMT knockdown in mice produced lean body composition despite a high-fat diet, improved glucose tolerance, and increased energy expenditure, establishing NNMT as a legitimate metabolic target. The 5-amino-1MQ molecule provides a pharmacologic tool to test whether inhibiting NNMT pharmacologically reproduces the benefits of genetic knockdown, and preclinical studies using 5-amino-1MQ and related inhibitors in diet-induced obese mice have demonstrated reduced adiposity, improved insulin sensitivity, and lower hepatic triglyceride content (Kannt et al., 2018). The compound has attracted attention in the fitness and longevity biohacking communities because of a separate line of research suggesting that NNMT inhibition may improve skeletal muscle function during aging by preserving NAD+ availability and altering methyl group metabolism in ways that favor muscle regeneration. A widely circulated 2021 study in aged mice reported that 5-amino-1MQ administration increased muscle stem cell activity, improved muscle regeneration after injury, and increased grip strength and muscle mass in older animals. This finding, combined with the obesity data, generated substantial interest in 5-amino-1MQ as a dual-purpose metabolism-and-sarcopenia compound, which has driven significant sales through research-chemical vendors despite the complete absence of human clinical trials. The practical reality of 5-amino-1MQ as a research chemical in April 2026 mirrors the situation with BAM15 and similar compounds: preclinical evidence is genuinely interesting, mechanism is plausible, regulatory development is nonexistent, and users are self-experimenting with research-chemical-vendor supply at unvalidated doses. This entry covers what 5-amino-1MQ actually does at the enzyme level, what the preclinical studies in obesity and muscle have shown, what the methyl-donor and NAD+ biology implies about stacking decisions, what the real concerns are about long-term NNMT inhibition (cancer surveillance, methylation homeostasis, interactions with other epigenetic processes), and what a defensible approach looks like for anyone considering experimentation. The honest summary: 5-amino-1MQ is a legitimate research compound targeting a real metabolic pathway, the rodent data are reproducible across multiple labs, and there is zero direct human evidence that the compound is safe or effective at any dose. FDA-approved interventions for obesity and metabolic disease (Semaglutide, Tirzepatide, Retatrutide, bariatric surgery, lifestyle medicine) have Phase 3 data and offer predictable benefit-risk profiles that 5-amino-1MQ does not. For sarcopenia, resistance training remains the dominant evidence-based intervention, and no pharmacologic intervention has demonstrated superiority to well-dosed protein and progressive overload in older adults. 5-amino-1MQ sits alongside these validated options as an investigational compound of mechanistic interest, not as a substitute for them.

Also known as: MOTS-c

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide — a member of a recently discovered class of small peptides encoded in mitochondrial DNA rather than nuclear DNA. It was first characterized and named by Lee et al. in 2015 at Pinchas Cohen's laboratory at USC, representing a paradigm shift in mitochondrial biology: the mitochondria are not merely recipients of nuclear regulatory signals, they produce their own signaling peptides that act both locally and systemically on metabolism. The MOTS-c sequence (M-R-W-Q-E-M-G-Y-I-F-Y-P-R-K-L-R-H) is encoded in the 12S rRNA region of mitochondrial DNA. Under metabolic stress conditions — fasting, caloric restriction, exercise — mitochondria translate and release MOTS-c into circulation, where it acts as an exercise-mimetic and metabolic regulator with primary effects on skeletal muscle, adipose tissue, and liver. The core pharmacologic mechanism is AMP-activated protein kinase (AMPK) agonism, the same metabolic master-switch targeted by metformin, exercise, and caloric restriction. AMPK activation drives: GLUT4 translocation to the muscle cell membrane → increased glucose uptake Fatty acid oxidation upregulation via ACC phosphorylation Mitochondrial biogenesis via PGC-1α pathway Inhibition of de novo lipogenesis and gluconeogenesis Improved insulin sensitivity at multiple tissue sites Preclinical studies document striking effects: MOTS-c treatment in diet-induced obese mice produces weight loss, restored insulin sensitivity, normalized glucose tolerance, and enhanced exercise capacity (Lee 2015; Reynolds 2021). In aging studies, MOTS-c administration to aged mice restores exercise performance to that of young animals and reverses age-related metabolic dysfunction (Reynolds 2021). Importantly, endogenous MOTS-c levels decline with aging and are suppressed in metabolic disease states. This has generated the hypothesis that declining MDP production is a causal contributor to age-related metabolic decline — positioning MOTS-c replacement as a potential longevity intervention analogous to hormone replacement, though the evidence base is still primarily preclinical. MOTS-c is not FDA-approved for any indication. Research-chemical use for metabolic tuning, athletic performance, and longevity purposes is emerging but limited; typical protocols use 5-10 mg SC 2-3 times weekly. Human pilot data is scarce; most efficacy inferences come from animal models and mechanistic plausibility.

Also known as: BAM-15

BAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (Kenwood et al., 2014). The full chemical name is (2-fluorophenyl)-(6-(2-fluorophenyl)amino)amine, molecular weight 338.3 g/mol, and the molecule was identified through a high-throughput screen designed to find uncouplers that behave differently from the classical reference compound 2,4-dinitrophenol (DNP). DNP raises metabolic rate and causes rapid fat loss in animals and humans but has a catastrophically narrow therapeutic window, with hyperthermia, cataracts, peripheral neuropathy, and fatal overdoses well documented in the 1930s weight-loss literature and in modern case series of bodybuilders and diet pill users who source DNP as a research chemical (Grundlingh et al., 2011). BAM15 was explicitly designed to improve on DNP by restricting uncoupling activity to mitochondria and not the plasma membrane, theoretically producing the metabolic benefit — increased substrate oxidation, reduced reactive oxygen species, improved insulin sensitivity — without the cardiovascular and thermoregulatory toxicity that makes DNP untenable as a drug. If you are on this page because you heard BAM15 called "a safe DNP" on a forum or podcast, you should finish this entry before you do anything else. BAM15 is a research chemical. There are zero published clinical trials in humans as of April 2026, zero FDA-approved indications, zero pharmacokinetic or toxicology studies in people, and zero manufacturers producing it under pharmaceutical-grade quality standards for human use. Every dose anyone has ever taken has come from a research-chemical vendor with no regulatory oversight. The preclinical animal data are genuinely exciting — BAM15 reverses diet-induced obesity in mice at doses that appear well tolerated, improves hepatic steatosis in rodent NASH models, lowers blood glucose, improves insulin sensitivity, and reduces ROS generation without the hyperthermia and death that DNP produces at comparable efficacy doses. But "better than DNP in mice" is an extremely low bar, and the gap between "promising in rodents" and "safe in humans at a predictable dose" is exactly where hundreds of drug candidates have died over the last two decades. This entry is a complete summary of what BAM15 actually does mechanistically, what the preclinical evidence shows, what it does not show, why there are no human trials despite a decade of academic interest, and what the realistic landscape looks like for anyone considering experimenting with it. We will talk about the pharmacology in enough detail that you can have an informed conversation with a physician about why you should probably not be using this compound, and we will also be honest that a subset of people will use it anyway, in which case the harm-reduction information below — dose ranges reported in self-experimenters, signs of mitochondrial toxicity, interactions with other metabolic agents, and the reasons no one has been able to bring this drug to a Phase 1 trial despite its theoretical advantages — becomes the most important part of the page. Uncoupler chemistry is one of the few mechanisms in metabolism that cannot be meaningfully replicated by training, diet, or lifestyle intervention. Exercise, cold exposure, fasting, and caloric restriction all activate mitochondrial biogenesis and uncoupling protein expression (UCP1, UCP2, UCP3), which is the body's own physiological version of uncoupling. Those interventions should be fully optimized before anyone looks at a chemical protonophore, because physiological uncoupling through brown adipose tissue activation, exercise-induced mitochondrial adaptation, and UCP upregulation delivers a substantial fraction of the metabolic benefit with none of the drug-risk profile. BAM15 exists in the conversation because people want a pill version of cold exposure and cardio. That desire is legitimate, but the pill does not yet exist in a form any reasonable clinician would recommend.

Also known as: Carnitine, LCAR

L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health. Chemically classified as a conditionally essential nutrient, it is stored primarily in skeletal muscle (about 95% of total body carnitine, roughly 20 grams in an adult), with smaller pools in the liver, brain, heart, kidneys, and sperm. The body makes carnitine, but dietary intake — primarily from red meat and dairy — is the dominant source for most people. Vegans and vegetarians have measurably lower plasma carnitine levels, though this does not typically translate into overt deficiency in otherwise healthy individuals. The fundamental biological role of L-carnitine is to shuttle long-chain fatty acids across the inner mitochondrial membrane, where they undergo beta-oxidation to produce ATP. Without adequate carnitine, long-chain fatty acids cannot enter mitochondria for energy production, and lipid metabolism grinds to a halt. This mechanism explains why carnitine is especially important for tissues with high fatty acid oxidation demands: cardiac muscle (which derives 60-90% of its energy from fat), skeletal muscle (during extended exercise), and sperm (which use fatty acid oxidation for motility). The "carnitine shuttle" is one of the core metabolic cycles in mammalian biochemistry (Longo et al., 2016). L-Carnitine exists in several supplemental forms, and the choice matters. L-carnitine (plain L-carnitine, sometimes called L-carnitine tartrate) is the standard form — well-absorbed, supports general fatty acid metabolism, the form used in most cardiovascular and metabolic research. Acetyl-L-carnitine (ALCAR) has an acetyl group attached that allows it to cross the blood-brain barrier more effectively, giving it specific cognitive and neuroprotective applications — this is the form used in most studies of cognitive aging, mild cognitive impairment, and peripheral neuropathy. L-carnitine L-tartrate (LCLT) is a salt form with enhanced stability and is the specific form used in most exercise performance and recovery research. Propionyl-L-carnitine (PLC) has a propionyl group instead of an acetyl group and is specifically studied for peripheral artery disease and endothelial function. Glycine propionyl-L-carnitine (GPLC) is a further modification marketed for exercise performance. These are not interchangeable — research findings with one form do not automatically generalize to others (Pennisi et al., 2020). The clinical evidence base for L-carnitine is deeper than most supplements. Cardiovascular disease — particularly heart failure, post-myocardial infarction recovery, and angina — has been the subject of multiple randomized trials and meta-analyses showing mortality reduction and symptomatic improvement. Peripheral artery disease with intermittent claudication has strong evidence for propionyl-L-carnitine specifically. Chronic fatigue and fatigue-related conditions including post-chemotherapy fatigue and HIV-associated fatigue have multiple supporting trials. Male fertility — carnitine improves sperm motility, concentration, and morphology in men with oligoasthenospermia. Cognitive aging — ALCAR has multiple trials in mild cognitive impairment and Alzheimer's disease with modest but consistent benefits. Peripheral neuropathy — ALCAR has good evidence for diabetic and chemotherapy-induced neuropathy. Hemodialysis patients — carnitine deficiency is common in dialysis, and IV L-carnitine is FDA-approved for this indication (DiNicolantonio et al., 2013, Pennisi et al., 2020). The research peptide and performance community uses L-carnitine mostly for two broad purposes: fat loss support and exercise recovery. For fat loss, the theory is straightforward — more carnitine should improve fatty acid transport into mitochondria and therefore improve fat oxidation. The practical evidence for fat loss is modest at best; L-carnitine is not a meaningful standalone weight loss agent, but it may support fat oxidation in specific contexts (particularly in carnitine-deficient states or with appropriate training). For exercise recovery, L-carnitine L-tartrate (LCLT) has a more solid evidence base — multiple trials show reduced muscle damage markers, faster recovery between sessions, and improved recovery markers in resistance-trained individuals at 2-3 g daily (Volek et al., 2002, Spiering et al., 2008). L-Carnitine has a complex relationship with the microbiome that has generated controversy. Dietary L-carnitine is metabolized by gut bacteria to produce TMAO (trimethylamine-N-oxide), a compound that has been associated in observational studies with increased cardiovascular risk. This finding — that the same compound used therapeutically for cardiovascular disease may also produce a putatively atherogenic metabolite — created significant debate. Subsequent work has suggested the TMAO-cardiovascular link may be more correlational than causal, that supplemental L-carnitine produces different TMAO responses than dietary sources in some populations, and that the net cardiovascular effect of L-carnitine in randomized trials remains favorable. The picture is more nuanced than initial headlines suggested (Koeth et al., 2013, Samulak et al., 2019). L-Carnitine is not a research peptide in the sense of BPC-157 or Semax — it is a well-characterized nutritional/metabolic compound with decades of clinical use, FDA-approved forms (Carnitor IV for dialysis patients, Levocarnitine for primary and secondary carnitine deficiency), and widespread availability as a supplement. This gives the evidence base a quality and depth that most "research peptides" lack. At the same time, L-carnitine is not a miracle compound. Its effects in healthy individuals without deficiency are modest. Its role is best understood as metabolic effect — filling a specific cofactor function — rather than as a primary therapeutic intervention. The honest framing for anyone considering L-carnitine: it has real biology, real evidence, and real clinical use. It is not going to transform your body composition or athletic performance in healthy individuals with adequate diet. It may be meaningfully useful in specific contexts: vegan/vegetarian supplementation, aging (where tissue carnitine declines), heart failure, peripheral artery disease, chronic fatigue, male fertility, cognitive aging, and dialysis patients. Beyond those contexts, use is supportive rather than transformative, and cost-benefit needs honest evaluation.

Also known as: MIC injection

Lipotropic compound blend injection

Also known as: Berberine HCl, Berberine Hydrochloride, Umbellatine, Natural Metformin, Berberis Alkaloid, Dihydroberberine (DHB, reduced form), Coptisine (related alkaloid), Goldenseal Alkaloid

Berberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi). Its use in traditional medicine spans more than two millennia, with documented applications in Traditional Chinese Medicine (under the name Huang Lian Θ╗äΦ┐₧, primarily from Coptis chinensis), Ayurveda (from Berberis aristata, called Daruharidra or "tree turmeric"), Native American medicine (from goldenseal, Hydrastis canadensis), and Persian medicine (from Berberis vulgaris). Traditional indications emphasized gastrointestinal complaints — diarrhea, dysentery, intestinal infection — which turn out to align well with berberine's documented antimicrobial activity against bacteria, protozoa, and fungi. The modern pharmacologic investigation of berberine dates to the mid-20th century with early studies on antibacterial and antidiarrheal effects, but the explosion of contemporary interest followed the 2004 discovery by Kong and colleagues (PMID 15467988) that berberine lowers blood lipids through a mechanism involving LDL receptor upregulation. This finding redirected berberine research toward metabolic applications — diabetes, dyslipidemia, polycystic ovary syndrome, non-alcoholic fatty liver disease, and metabolic syndrome — and positioned berberine as a botanical analog to pharmaceutical metformin. The landmark Yin et al. 2008 randomized controlled trial (PMID 18397984) compared berberine 500 mg three times daily head-to-head with metformin 500 mg three times daily in 36 adults with newly-diagnosed type 2 diabetes over three months, finding comparable glycemic effects: HbA1c reduction of approximately 2 percentage points with berberine versus similar reduction with metformin, and with superior lipid effects (significant triglyceride and total cholesterol reductions exceeding what metformin produced). This single trial, though small, catalyzed the modern "natural metformin" marketing positioning that continues to drive berberine's commercial growth in the functional medicine and longevity supplement space. Since then, dozens of clinical trials and several meta-analyses have examined berberine across diabetes, dyslipidemia, metabolic syndrome, PCOS, hypertension, and various gastrointestinal indications. The accumulating evidence has generally supported berberine's metabolic effects but with important nuances: the bioavailability of oral berberine is less than 1%, meaning the vast majority of an ingested dose is never systemically absorbed; effects on distal organs therefore depend substantially on metabolites, gut microbiome modulation, and intestinal signaling rather than direct tissue exposure; effects on glucose and lipids are strong and reproducible but typically modest in magnitude (similar to metformin rather than superior to it in rigorous trials); meaningful pharmacokinetic drug interactions occur via cytochrome P450 inhibition, particularly CYP3A4 and CYP2D6, which must be considered for patients taking prescription medications metabolized by these pathways. Berberine has also entered the longevity and healthspan conversation as an AMPK activator — AMPK being one of the central nutrient-sensing pathways whose activation is believed to underlie at least some of the age-slowing effects of caloric restriction, metformin, and rapamycin-independent pathways. Whether berberine meaningfully extends healthspan in humans has not been demonstrated (the evidence for this is lower than for metformin, which itself has debated longevity evidence), but mechanistic rationale and safety profile have made it a common addition to longevity-oriented supplement stacks. Other prominent applications include: gastrointestinal applications in small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome, based on berberine's antimicrobial activity and favorable microbiome modulation; PCOS management, where Lan et al. 2015 (PMID 25935511) documented improvements in insulin resistance and menstrual regularity; non-alcoholic fatty liver disease, with trials showing hepatic steatosis reduction; and cholesterol management, where berberine's LDL receptor upregulation provides a statin-alternative for individuals with statin intolerance. The bioavailability problem has driven development of several alternative formulations: dihydroberberine (the reduced form, with theoretically superior absorption); phytosome formulations binding berberine to phosphatidylcholine to improve intestinal uptake; liposomal formulations; and combinations with P-glycoprotein inhibitors like silymarin to prevent efflux back into the intestinal lumen. Whether these formulations produce meaningfully superior clinical outcomes versus standard berberine HCl remains unclear, as most were developed for pharmacokinetic rather than efficacy endpoints. This entry covers berberine's mechanism (AMPK activation, gut-microbiome mediated effects, intestinal L-cell DPP-4 inhibition, lipid-modulating effects via LDL receptor and PCSK9 pathways); the clinical evidence base (glycemic effects, lipid effects, PCOS, NAFLD, weight, and gastrointestinal applications); the pharmacokinetic challenges (low bioavailability, CYP-mediated drug interactions, first-pass metabolism); formulation alternatives (dihydroberberine, phytosomes, liposomes); practical dosing considerations; and appropriate integration into metabolic, longevity, and gastrointestinal supplement protocols alongside metformin, NMN, TUDCA, NAC, CoQ10, curcumin, and other evidence-based interventions.

Also known as: Clen, Spiropent, Ventipulmin, Dilaterol, Novegam, NAB-365, 4-amino-alpha-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol

Clenbuterol is a long-acting, selective beta-2 adrenergic receptor agonist originally developed in the late 1970s by Thomae GmbH (later Boehringer Ingelheim) as a bronchodilator for obstructive airway disease. Structurally it is a sympathomimetic amine — 4-amino-alpha-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol — with a catecholamine-like pharmacophore but with the catechol hydroxyls replaced by a dichloroanilino group that dramatically extends its plasma half-life (~26-36 hours in humans) compared to endogenous catecholamines (minutes). It was approved for human use as an asthma and chronic obstructive pulmonary disease bronchodilator in several European countries (Germany, Italy, Spain, Bulgaria, Russia) and throughout Latin America under brand names Spiropent, Dilaterol, Novegam, and Broncoterol, where it is typically dispensed as 20-microgram tablets or syrup. It was never approved for human use in the United States, United Kingdom, Canada, or Australia; in the US it is FDA-approved only as Ventipulmin, a veterinary bronchodilator for horses with recurrent airway obstruction (heaves). Despite lacking human FDA approval, clenbuterol has become one of the most widely misused performance-improving compounds in bodybuilding, strength athletics, and physique contest preparation, primarily because of two pharmacologic properties that extend beyond its bronchodilator indication: sustained thermogenesis (increased resting energy expenditure via uncoupling protein induction and beta-2-mediated metabolic effects) and skeletal muscle hypertrophy in animal models (via beta-2 receptor stimulation of type II muscle fiber protein synthesis pathways). The combination produces, on paper, a "repartitioning" effect — fat loss with preservation or gain of lean mass — that is the holy grail of contest preparation pharmacology. In practice, the human evidence for this effect at bodybuilding doses is essentially absent (no placebo-controlled trials have examined clenbuterol for fat loss in healthy humans), the cardiotoxicity is substantial, and the case reports of serious adverse events are numerous. Clenbuterol is banned by the World Anti-Doping Agency (WADA) under S1.2 "Other Anabolic Agents" and has been responsible for high-profile doping cases in cycling, baseball, track and field, and combat sports. The compound is additionally notorious for a unique contamination route: in several countries (notably Mexico and China during the 2000s-2010s), livestock producers illegally fed clenbuterol to cattle and pigs to increase lean yield at slaughter, resulting in residues in meat sufficient to produce mass poisoning events and inadvertent doping of athletes who ate contaminated meat. Clenbuterol's chemical profile of slow clearance, high potency (effective human doses in the tens of micrograms), and widespread grey-market availability — sold as "research chemical," liquid oral solutions, or smuggled foreign pharmaceutical tablets — has created a distinctive risk landscape. Users commonly escalate doses aggressively to overcome receptor desensitization, leading to cumulative cardiac stress, electrolyte derangements, rhabdomyolysis, and tachyarrhythmias that have produced multiple documented hospitalizations and some fatalities. The published case report literature contains dozens of clenbuterol-related emergency presentations including ventricular tachycardia, atrial fibrillation, takotsubo cardiomyopathy, acute myocardial infarction in structurally normal coronaries, severe hypokalemia (K+ < 2.5 mEq/L), and skeletal muscle necrosis. This entry covers clenbuterol's legitimate pharmacology as a bronchodilator, the animal and human evidence base for its off-label performance-improving uses, the cardiovascular toxicology that makes it genuinely dangerous, the WADA status and contaminated-meat issue, and provides honest framing about why BodyHackGuide does not recommend clenbuterol for fat loss or muscle-sparing purposes regardless of dose or cycle structure. Safer alternatives for the same goals (targeted caloric restriction, resistance training, moderate caffeine, green tea catechins, and — if medically indicated and prescribed — short-term GLP-1 agonists for obesity) are discussed in the stacking and protocol sections.